John P. Mulhall, MD, discusses the significant sexual and non-sexual adverse events of low testosterone resulting from using androgen deprivation therapy (ADT) to treat men with prostate cancer. He emphasizes the need for physicians to counsel patients on long-term expectations and to obtain fully-informed consent prior to the initiation of this therapy.
Read More
John P. Mulhall, MD, discusses the results and implications of a study evaluating the relationship between testosterone and PSA levels in men with prostate cancer. He suggests that these findings indicate that in men with documented prostate cancer, the presence of a pretreatment PSA value below 2 should raise questions about a patient’s testosterone level.
Read More
John P. Mulhall, MD, the chair of the committee for the American Urological Association (AUA) testosterone guidelines, summarizes indications regarding anejaculation. He explains the anatomical and physiological differences of retrograde ejaculation and failure of emission, and possible etiologies for these symptoms. Furthermore, he reviews the recommendations for diagnosis, management, and use of electroejaculation for semen retrieval.
Read More